Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

Larissa C. Faustino, George J. Kahaly, Lara Frommer, Erlinda Concepcion, Mihaela Stefan-Lifshitz and Yaron Tomer

Background: CD40, a key co-stimulatory molecule expressed on antigen-presenting cells, is genetically associated with a number of autoimmune diseases including Graves’ disease (GD). Therefore, recent therapies targeting CD40 have been developed, including the anti-CD40 monoclonal antibody Iscalimab. In a recent pilot study, Iscalimab was shown to induce clinical remission in ~ 50% of GD patients, but the reason why only 50% of GD patients responded is not known. The aim of our study was to test the hypothesis that specific CD40 single nucleotide polymorphism (SNP) genotypes and haplotypes are associated with clinical response of GD patients to Iscalimab.

Methods: We extracted genomic DNA from the whole blood of 13 GD patients treated with Iscalimab, and genotyped seven CD40 single nucleotide polymorphisms (SNPs) associated with autoimmunity. Additionally, we analyzed CD40 mRNA expression levels in whole blood. The patients’ CD40 SNP genotypes and mRNA levels were tested for association with clinical response to Iscalimab.

Results: Three common haplotypes, designated haplotypes A, B, and C, were identified. Haplotypes B and C were associated with higher CD40 mRNA levels and clinical response to Iscalimab (i.e., patients achieving euthyroidism without need for additional medications), while haplotype A was associated with decreased CD40 mRNA levels and no response to Iscalimab.

Conclusion: Our data suggest that genetic polymorphisms in the CD40 gene drive its expression levels and response to Iscalimab. Polymorphisms associated with higher CD40 levels are also associated with clinical response to CD40-targeted therapies. These results set the stage to implementing precision medicine in the therapeutic approach to GD.

Keywords: gene, CD40, variant, Graves’ disease, precision medicine
INTRODUCTION

Graves’ disease (GD) is one of the most common organ-specific autoimmune diseases affecting 1% to 2% of the adult population in the US (1, 2). GD is characterized by infiltration of the thyroid with autoreactive T-cells, and the production of thyrotropin receptor (TSHR) autoantibodies (Ab) that activate the TSHR and lead to the clinical manifestations of thyrotoxicosis and diffuse goiter (3, 4). Currently the treatment of GD is still based on three options: thionamides, radioactive iodine ablation of the gland, or surgical resection of the thyroid gland (5). All three therapeutic options for GD are aimed at suppressing the thyrotoxicosis but not at reversing the underlying autoimmune process. Therefore, patients are often difficult to manage and euthyroidism difficult to achieve (6–8). Even in patients that achieved biochemical euthyroidism with T4 replacement (after thyroid ablation) many still report symptoms and reduced quality of life (9–11). Therefore, there is a need for new curative therapies for GD targeting the autoimmune mechanisms underlying the disease. One such novel and exciting new therapy has been the development of a monoclonal antibody, Iscalimab (CFZ533), which targets the co-stimulatory molecule CD40 (12, 13).

Since CD40 has been shown to play a role in a number of autoimmune diseases including GD (14–17), Iscalimab has begun preliminary testing in several autoimmune conditions including myasthenia gravis (18), rheumatoid arthritis (19), Sjogren’s syndrome (20), and systemic lupus erythematosus (SLE) (21). Recently, Iscalimab (CFZ533) was reported to show potential effectiveness in a pilot study of 15 GD patients (22). All GD patients treated with Iscalimab showed significant reduction in TSHR-Ab, and 7 of 15 patients achieved biochemical euthyroidism (22). However, it is presently not known why only a subset of ~50% of patients responded. One potential explanation is that genetic variations at the CD40 gene-locus affect the clinical response to CD40-targeted therapies. We have previously identified a functional CD40 C/T single-nucleotide polymorphism (SNP) (rs1883832) that was associated with GD (14, 23). Following our discovery of the association of rs1883832 with GD, other CD40 SNPs were reported to be associated with autoimmunity [rs6074022 (24); rs745307, rs4810485, rs11569309, and rs3765457 (14, 15, 24–26), and another intergenic SNP, rs112809897, downstream the CD40 gene between the CD40 and CDH22 genes. These seven SNPs were genotyped using the Taqman allelic discrimination assays (Thermo-Fisher Scientific, Waltham, MA) as previously described (27). SNP positions and locations are shown in Table 1.

TABLE 1 | Distances and locations of the seven SNPs analyzed.

| SNP      | bp (hg38 Assembly) | Distance between SNPs | Location               |
|----------|--------------------|-----------------------|------------------------|
| rs6074022 | 46,111,557         | 0                     | Promoter               |
| rs1883832 | 46,118,343         | 6,786                 | Kozak sequence         |
| rs745307  | 46,118,447         | 104                   | intron 1               |
| rs4810485 | 46,119,308         | 861                   | intron 1               |
| rs11569309| 46,119,911         | 603                   | intron 1               |
| rs3765457 | 46,128,574         | 8,663                 | intron 8               |
| rs112809897| 46,149,941         | 21,367                | Intergenic region      |

DNA Purification and Genotyping

Genomic DNA was extracted and purified from whole blood using the QIAamp DNA blood kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. We genotyped six CD40 SNPs, previously shown to be associated with autoimmunity: rs6074022, rs1883832, rs745307, rs4810485, rs11569309, and rs3765457 (14, 15, 24–26), and another intergenic SNP, rs112809897, all located at the chromosome 20q CD40 locus. For the LD and haplotype analyses we generated a pedigree (PED) file using the VCF to PED converter in the Ensembl database (https://useast.ensembl.org/index.html) for the CEU population. The generated PED file was then uploaded to the Haplovie program which was used to perform the LD and haplotype analyses for the selected region containing these seven patients that participated in the Iscalimab study. For a detailed description of the study protocol, inclusion and exclusion criteria, and outcomes see (22). Briefly, GD patients were enrolled at the endocrine clinic of the JGU Medical Center. GD was diagnosed by evidence of biochemical hyperthyroidism with thyrotoxic symptoms, and positive TSHR-Ab measured by the Roche Cobas Elecsys electrochemiluminescence immunoassay (Roche Diagnostic Corporation). The treatment period lasted 12 weeks and patients received 10 mg/kg Iscalimab IV at weeks 0, 2, 4, 8, and 12. Patients were followed up for 24 weeks after completing the Iscalimab treatment course. Worsening disease at follow-up was defined as relapse of symptoms and signs of thyrotoxicosis, or significant increase in serum thyroid hormone levels requiring additional medications. Response to Iscalimab was defined as normalization of thyroid functions at the completion of the study without the need for additional medications. Partial response was defined as normalization of peripheral free thyroid hormones with persistently suppressed serum TSH.

Linkage Disequilibrium and Haplotype Analyses

Linkage disequilibrium (LD) and haplotype analyses were performed for SNPs rs6074022, rs1883832, rs745307, rs4810485, rs11569309, rs3765457, and rs112809897, all located at the chromosome 20q CD40 locus. For the LD and haplotype analyses we generated a pedigree (PED) file using the VCF to PED converter in the Ensembl database (https://useast.ensembl.org/index.html) for the CEU population. The generated PED file was then uploaded to the Haplovie program which was used to perform the LD and haplotype analyses for the selected region containing these seven

MATERIALS AND METHODS

Study Design

For full details of the study design see (22). The project was approved by the Johannes Gutenberg University (JGU) Medical Center Institutional Review Board and all patients provided signed informed consent. We analyzed DNA purified from...
SNPs (28, 29). Haplotypes identified by Haploview were then analyzed and confirmed manually in our patients.

Quantification of CD40 RNA Levels Using RT-qPCR

Total RNA was purified from whole blood using QIAamp RNA blood kit (Qiagen) according to the manufacturer’s instructions. Total RNA was reverse transcribed using the Superscript III kit (Thermo Fisher Scientific) and RT-qPCR analyses were performed in a fluorescent temperature cycler (ABI PRISM 7300, Applied Biosystems). The sequences for the forward and reverse primers (Integrated DNA Technologies) were as follows: CD40: 5’-AAAT GTCACCCTTGGACAAGCT-3’ and 5’-TTGTCCTGCCCT GTTGCA-3’; GAPDH: 5’-ATGGAATTCCATCACCATCTT-3’ and 5’-CGCCCCACTTGATTTTGG-3’. After an initial incubation at 50°C for 2 min and 95°C for 10 min, the reactions were cycled 40 times using the following parameters: 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. SYBR Green (Applied Biosystems) fluorescence was detected at the end of each cycle. The expression of CD40 was normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by calculating the ΔCt of CD40 vs. GAPDH. We then calculated the ΔΔCt for each patient using the mean ΔCt for individuals carrying haplotype A as the reference expression levels. The fold change in CD40 mRNA expression levels (relative to the mean expression levels in individuals carrying haplotype A) was then determined using the 2−ΔΔCt formula. All assays were repeated three times, and the averages of three experiments are shown. The results are expressed as fold change in CD40 mRNA levels relative to mean CD40 mRNA expression levels in individuals carrying haplotype A.

Statistical Analyses

Statistical analyses were performed using the GraphPad Prism version 5.0 software. We used the Fisher exact test to test for association between CD40 SNP haplotypes and clinical response to Iscalimab treatment. The unpaired Student’s t-test was used to compare CD40 mRNA expression levels in GD patients carrying haplotype A vs. patients carrying either haplotype B or C. p < 0.05 was considered significant.

RESULTS

Characteristics of Hyperthyroid GD Patients Treated With Iscalimab

Our cohort included 13 GD patients treated with Iscalimab (two patients from the original cohort (22) were not available for testing). GD was diagnosed as described above. Table 2 shows the clinical, demographic, and serologic characteristics of the study patients, as well as their response to treatment with Iscalimab. The majority of patients were Caucasian women and the mean age was 49 years. Of the 13 patients included in our study 8 (61.5%) showed either response (7/13) or partial response (1/13) to Iscalimab as shown by decreased TSHR-Ab levels and/or normalizations of thyroid functions.

Linkage Disequilibrium and Haplotype Analyses

Linkage disequilibrium (LD) analysis, performed using Haploview, revealed tight LD between the six SNPs located in the promoter, 5’UTR, and introns of CD40 (rs6074022, rs1883832, rs745307, rs4810485, rs11569309, rs3765457) due to the close distances between them (Figure 1). Therefore, our haplotype analysis identified haplotypes for these six SNPs only. Haplotype analysis was performed using the Haploview program (28, 29) for the CEU population (see Methods). Haplotypes identified by Haploview in the CEU population were verified in our patients by manual analysis. We identified eight distinct haplotypes that we designated as A–H (Table 3). Of them, five were identified in both the CEU population and our patients (A–E; Table 3), one was identified only in the CEU population (F; Table 3) and two were identified only in our patients (G, H; Table 3). Of these eight haplotypes we identified three dominant haplotypes in our patients that were strongly associated with clinical response to Iscalimab (see below): Haplotype A (CTGTTAC); haplotype B (TCGGTAC); and haplotype C (TCAGTAC) (Table 3).

Association Between CD40 SNP Haplotypes and Clinical Response to Iscalimab

Of the 13 patients in our cohort, eight responded to Iscalimab and five did not respond (Table 2). As shown in Table 4 all eight

---

**Table 2** | Characteristics of the cohort of Graves’ disease (GD) patients analyzed in the study.

| Patient | Age | Gender | Ethnicity | GD: New/Relapse | GO | Smoking | Baseline TSHR-Ab | Baseline TPO-Ab | Baseline Tg-Ab | Response to Iscalimab |
|---------|-----|--------|-----------|----------------|-----|---------|------------------|----------------|---------------|------------------------|
| 1       | 40  | F      | Caucasian | New            | Yes | No      | 151.5            | 915            | 125.1         | Non-responder         |
| 2       | 40  | F      | Caucasian | Relapse        | No  | No      | 9.5              | 345            | 62.6          | Responder             |
| 3       | 51  | F      | Caucasian | New            | Yes | Yes     | 40.3             | >1000          | 780.6         | Responder             |
| 4       | 24  | M      | Caucasian | Relapse        | Yes | Yes     | 171.3            | 193            | 1.3           | Responder             |
| 5       | 19  | F      | Caucasian | New            | No  | Yes     | 11.4             | 122            | 3.4           | Responder             |
| 6       | 49  | F      | Caucasian | Relapse        | Yes | Yes     | 33.3             | >1000          | 4             | Non-responder         |
| 7       | 26  | F      | Caucasian | New            | No  | No      | 56.8             | 876            | 143           | Responder             |
| 8       | 49  | F      | Caucasian | Relapse        | No  | No      | 6.7              | 977            | 6.3           | Non-responder         |
| 9       | 50  | M      | Caucasian | New            | Yes | Yes     | 48.3             | >1000          | 95            | Partial response       |
| 10      | 51  | F      | Caucasian | Relapse        | Yes | Yes     | 4.17             | 403            | 67            | Responder             |
| 11      | 52  | F      | Caucasian | Relapse        | No  | No      | 11.0             | 173            | 3.9           | Non-responder         |
| 12      | 65  | F      | Caucasian | Relapse        | No  | Yes     | 27.46            | 181            | 40.4          | Responder             |
| 13      | 53  | F      | Caucasian | Relapse        | No  | Yes     | 2.54             | 61             | 1             | Non-responder         |

Units and normal values of thyroid antibodies: TSHR-Ab, IU/L <1.75; TPO-Ab, IU/ml <25; Tg-Ab, IU/ml <40.
patients that had a clinical response to Iscalimab carried either haplotypes B (TCGGTA) or C (TCAGTA) and all five non-responders carried haplotype A (CTGTTA) \[p=0.0008, \text{using Fisher exact test}\]. Further analysis revealed three key SNPs differentiating responders from non-responders: rs6074022 (T allele associated with response to Iscalimab and C allele with no response), rs1883832 (C allele associated with response to Iscalimab and T allele with no response), and rs4810485 (G allele associated with response to Iscalimab and T allele with no response). Thus, using these three SNPs, haplotype TCG was associated with response to Iscalimab and haplotype CTT was associated with no response to Iscalimab (Table 4).

**Association Between Response to Iscalimab and CD40 mRNA Expression Levels**

We tested whether response to Iscalimab was also associated with CD40 mRNA expression levels in whole blood. mRNA levels of CD40 were significantly higher in responders to Iscalimab compared to non-responders \(p=0.046; \text{Table 4}\). Since all responders also carried haplotypes B or C and all non-responders carried haplotype A, this suggested that haplotypes B and C may drive higher expression levels of CD40, leading to clinical response to Iscalimab while haplotype A may drive lower expression of CD40 and reduced response to Iscalimab.

**DISCUSSION**

Precision medicine is a new field of medicine aimed at tailoring therapies to individual patients based on both the molecular mechanisms triggering their disease, as well as the patients’ unique genetic variants \(30\). Precision medicine has the potential to revolutionize medical care as tailoring treatments to individual patients will maximize the efficacy of medications while minimizing their side effects \(31\).
have been many exciting developments in precision medicine approaches for autoimmune diseases (32, 33). Our study demonstrated, for the first time, that precision medicine could potentially be applied to the treatment of GD. We have shown in a pilot cohort of GD patients an association between specific CD40 SNP haplotypes, as well as CD40 mRNA expression levels and clinical response to CD40 targeted therapy with Iscalimab (Table 4). Therefore, if our data are confirmed in larger cohorts, it will enable precision tailoring of CD40 targeted therapies to individual patients carrying the B or C haplotypes and/or having higher CD40 mRNA levels in their blood (Table 4).

Genetic susceptibility has long been recognized to play a pivotal role in the etiology of GD (34). The CD40 gene, expressed on antigen-presenting cells, such as dendritic cells and B-cells (35), was shown to be a key susceptibility gene for GD (14), as well as other autoimmune diseases (15–17). We have previously mapped a functional SNP in the CD40 Kozak-sequence, rs1883832, that was associated with GD (14). Furthermore, we have shown that the GD risk allele (C) increased the expression of CD40 (23, 36), and that increased expression of CD40 on thyroid cells was associated with targeting the autoimmune response to the thyroid in GD (37, 38). The association of CD40 with GD has now been confirmed in many studies in different ethnic and geographic populations (39–45). Moreover, some studies have shown that CD40 polymorphisms can predict remission and relapse of GD (25, 44).

In view of the pivotal role of CD40 in the etiology of GD the newly developed monoclonal antibody, Iscalimab, which blocks CD40 activity, was tested in a cohort of GD patients, and was shown to be effective in reducing TSHR-Ab in all patients and normalizing thyroid hormone levels in ~ 50% of hyperthyroid GD patients (22). Our data showed that haplotypes B and C were significantly associated with response to therapy while all carriers of haplotype A were non-responders. Moreover, we found that individuals carrying haplotype A had lower CD40 mRNA expression in their blood than patients carrying haplotypes B and C. This finding could provide a mechanistic explanation for the lack of response to Iscalimab therapy in GD patients carrying haplotype A. Since patients carrying haplotypes B and C had significantly higher levels of expression of CD40, it is likely that genetically-driven CD40 over-expression played a major role in the development of GD in them (36, 37), and therefore blocking CD40 was an effective intervention in them. On the other hand, GD patients carrying haplotype A had very low levels of CD40 expression and therefore, CD40 probably did not play an important role in the etiology of GD in them and other mechanisms likely contributed.

Intriguingly, all three SNPs comprising haplotypes A, B, and C were previously shown to influence CD40 gene expression levels with the GD risk allele of each SNP consistently associated with significantly higher CD40 expression levels. SNP rs6074022, located in the promoter of CD40, has been shown to be associated with CD40 mRNA expression levels in whole blood from patients with multiple sclerosis (MS) and healthy controls. MS patients and controls carrying the TT (AA) genotype had significantly higher levels of CD40 mRNA compared to patients carrying the CT (GA) and CC (GG) genotypes (46). Consistent with these findings, in our study, the T allele of rs6074022 was associated with higher CD40 mRNA expression in whole blood compared to the C allele (Table 4). SNP rs1883832, located in the Kozak sequence of CD40, was shown by our group to be associated with CD40 expression, with the CC genotype associated with significantly higher protein expression levels of CD40 compared to the CT and TT genotypes (23, 36). These results were replicated in this study showing that the C allele of rs1883832 was associated with significantly higher levels of CD40 than the T allele (Table 4). Finally, SNP rs4810485, located in intron 1 of CD40, was also shown to be associated with CD40 mRNA and protein expression levels in PBMCs from patients with SLE and controls. The GG genotype was associated with significantly higher CD40 mRNA levels in PBMCs and significantly increased CD40 protein levels in peripheral blood CD14+ monocytes and CD19+ B cells compared to the GT and TT genotypes (16). Our findings are consistent with these data. We showed that the G allele of rs4810485 was associated with significantly higher CD40 levels compared with the T allele. However, since these three SNPs are in tight LD (Figure 1) it is not possible to determine which one is the causative SNP driving higher CD40 expression levels and clinical response to Iscalimab. Further studies are needed to determine which of these three SNPs is causative.

In conclusion, this was a pilot study on a small cohort of 13 GD patients. If our results are confirmed in larger cohorts, they set the stage to implementing precision medicine in the treatment of GD and potentially other autoimmune diseases. Genotyping of CD40 SNP variants could be utilized in pre-treatment screening potentially allowing clinicians to individualize treatment regimens based on a patient’s SNP genotype.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Johannes Gutenberg University (JGU) Medical Center Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
LF: Performed experiments, data analysis and interpretation, and participated in writing the manuscript. GK: Data collection, data analysis, and participated in writing the manuscript. LF: Data collection and participated in writing the manuscript. EC: Performed experiments. MS-L: Data interpretation and participated in writing the manuscript. YT: Conceptualization,
FUNDING

This work was supported in part by grants DK067555 & DK073681 from NIDDK (to YT). The JGU Medical Center, Mainz, Germany has received research-associated funding from Novartis, Cambridge, MA, USA to perform a phase II trial of Iscalimab in patients with Graves' disease (Clinical Trials Registration: NCT02713256). Novartis USA had no role in the present study design, data collection and analysis, decision to publish, or preparation of this manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.691781/full#supplementary-material

REFERENCES

1. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and Estimated Population Burden of Autoimmune Disorders in the United States. Clin Immunol Immunopathol (1997) 84:223–43. doi: 10.1006/ciim.1997.4412
2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. T(4), and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab (2002) 87(2):489–99. doi: 10.1210/jcem.87.2.8182
3. Davies TF, Tomer Y. Pathogenesis of Graves’ Disease. In: Braverman LE, Cooper DS, Kopp, editors. In: Werner and Ingbar’s The Thyroid: A Fundamental And Clinical Text. Philadelphia: Walters Kluwer (2020). p. 353–69.
4. Barbesino G, Tomer Y. Clinical Utility of TSH Receptor Antibodies. J Clin Endocrinol Metab (2013) 98(6):2247–55. doi: 10.1210/jc.2012-4309
5. Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves’ Disease. Nat Rev Dis Primers (2020) 6(1):52. doi: 10.1038/s41572-020-0184-y
6. Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and Factors Associated With Thyroid Hormone Over-Replacement and Under-Replacement in Men and Women Aged 65 and Over. J Clin Endocrinol Metab (2009) 94(4):1342–5. doi: 10.1210/jc.2008-1696
7. Ross DS, Burch HB, Cooper DS, Greenlee MC, Lauberg P, Maia AL, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid (2016) 26 (10):1343–421. doi: 10.1089/thy.2016.0229
8. Kahaly GJ, Bartalena I, Hegeduš L, Leenhardt L, Poppe K, Pearce SH. European Thyroid Association Guidelines for the Management of Graves’ Hyperthyroidism. Eur Thyroid J (2018) 7(4):167–86. doi: 10.1159/000490848
9. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological Well-Being in Patients on ‘Adequate’ Doses of L-Thyroxine: Results of a Large, Controlled Community-Based Questionnaire Study. Clin Endocrinol (Oxf) (2002) 57(5):577–85. doi: 10.1111/j.1365-2265.2002.01654.x
10. Welling EM, Appelhof BC, Flers E, Schene AH, Huysjer J, Tijssen JG, et al. Cognitive Functioning and Well-Being in Euthyroid Patients on Thyroxine Replacement Therapy for Primary Hypothyroidism. Eur J Endocrinol (2005) 153(6):747–53. doi: 10.1530/eje.1.02025
11. van de Ven AC, Netea-Maier RT, de Vogt F, Ross HA, Sweep FC, Kiemeney LA, et al. Is There a Relationship Between Fatigue Perception and the Serum Levels of Thyrotropin and Free Thyroxine in Euthyroid Subjects? Thyroid (2012) 22(12):1236–43. doi: 10.1089/thy.2011.0200
12. Ristov J, Espie P, Ulrich P, Sickert D, Flandre T, Dimitrova M, et al. Characterization of the In Vitro and In Vivo Properties of CFZ533, a Blocking and Non-Depleting Anti-CD40 Monoclonal Antibody. Am J Transplant (2018) 18(12):2895–904. doi: 10.1111/ajt.14872
13. Kahaly GJ, Management of Graves’ Hyperthyroidism and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab (2020) 105(12):3704–20. doi: 10.1210/clinem/dgaa546
14. Tomer Y, Concepcion E, Greenberg Da. A C/T Single-Nucleotide Polymorphism in the Region of the CD40 Gene Is Associated With Graves’ Disease. Thyroid (2002) 12(12):1129–35. doi: 10.1080/105072502321085234
15. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP. Common Variants at CD40 and Other Loci Confer Risk of Rheumatoid Arthritis. Nat Genet (2008) 40(10):1216–23. doi: 10.1038/ng.233
16. Vazgourakis VM, Zervou MI, Choulaki C, Melissourgaki M, Yi lmaz N, et al. A Common SNP in the CD40 Region Is Associated With Systemic Lupus Erythematosus and Correlates With Altered CD40 Expression: Implications for the Pathogenesis. Ann Rheumatic Dis (2011) 70(12):2184–90. doi: 10.1136/ard.2010.146536
17. Zervou MI, Goulidemos GN, Castro-Giner F, Bousamra DT, Tosca AD, Krueger-Krasagakis S. A CD40 and an NCOA5 Gene Polymorphism Confer Susceptibility to Psoriasis in a Southern European Population: A Case-Control Study. Hum Immunol (2017) 78(9):761–5. doi: 10.1016/j.jhimmun.2017.05.014
18. Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. Drugs (2019) 79(4):353–64. doi: 10.1007/s40265-019-1065-0
19. Espie P, He Y, Koo P, Sickert D, Dupuy C, Chokote E, et al. First-in-Human Clinical Trial to Assess Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Iscalimab, an Anti-CD40 Monoclonal Antibody. Am J Transplant (2020) 20(2):463–73. doi: 10.1111/ajt.15661
20. Mavragani CP, Moutsopoulos HM. Sjögren’s Syndrome: Old and New Therapeutic Targets. J Autoimmun (2020) 110:102364. doi: 10.1016/j.jaut.2019.102364
21. Narain S, Berman N, Fureie R. Biologics in the Treatment of Sjögren’s Syndrome, Systemic Lupus Erythematous, and Lupus Nephritis. Curr Opin Rheumatol (2020) 32(6):609–16. doi: 10.1097/BOR.0000000000000754
22. Kahaly GJ, Stan MN, Frommer L, Gergely P, Colin L, Amer A, et al. A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism- a Proof-of-Concept Trial. J Clin Endocrinol Metab (2020) 105(3):696–704. doi: 10.1210/clinem/dgq013
23. Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves’ Disease-Associated Kozak Sequence Single-Nucleotide Polymorphism Enhances the Efficiency of CD40 Gene Translation: A Case for Translational Pathophysiology. Endocrinology (2005) 146(6):2684–91. doi: 10.1210/en.2004-1617
24. Australia, New Zealand Multiple Sclerosis Genetics C. Genome-Wide Association Study Identifies New Multiple Sclerosis Susceptibility Loci on Chromosomes 12 and 20. Nut Genet (2009) 41(7):824–8. doi: 10.1038/ng.396
25. Wang PW, Chen Y, Jao SH, Hsi E, Liu RT, Hsieh CJ. Genotype and Phenotype Predictors of Relapse of Graves’ Disease After Antithyroid Drug Withdrawal. Eur Thyroid J (2013) 2(1):251–8. doi: 10.1159/000342621
26. Orozco G, Eyre S, Hinks A, Ke X, Wellcome Trust Case Control consortium YC, Wilson AG, et al. Association of CD40 With Rheumatoid Arthritis Confirmed in a Large UK Case-Control Study. Ann Rheum Dis (2010) 69 (3):813–6. doi: 10.1136/ard.2009.109579
27. Mallik M, Petersdorf EW. Genotyping of Single Nucleotide Polymorphisms by ’S Nucleate Allelic Discrimination. Methods Mol Biol (2012) 882:173–82. doi: 10.1007/978-1-61779-842-9_10
28. Tomer Y, Dolan LM, Kahaly G, Divers J, D'Agostino RB Jr, Imperatore G, et al. Genome Wide Identification of New Genes and Pathways in Patients With Both Autoimmune Thyroiditis and Type 1 Diabetes. J Autoimmun (2015) 60:32–9. doi: 10.1016/j.jaut.2015.03.006

Frontiers in Endocrinology | www.frontiersin.org
6 June 2021 | Volume 12 | Article 691781
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and Visualization of LD and Haplotype Maps. Bioinformatics (2005) 21(2):263–5. doi: 10.1093/bioinformatics/bti021

30. Ashley EA. Towards Precision Medicine. Nat Rev Genet (2016) 17(9):507–22. doi: 10.1038/nrg.2016.86

31. Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Aff (Millwood) (2018) 37(5):694–701. doi: 10.1377/hlthaff.2017.1624

32. Demirkaya E, Arici ZS, Romano M, Berard RA, Aksentijevich I. Current State of Precision Medicine in Primary Systemic Vasculitides. Front Immunol (2019) 10:2813. doi: 10.3389/fimmu.2019.02813

33. Tomer Y. Mechanisms of Autoimmune Thyroid Diseases: From Genetics to Epigenetics. Annu Rev Pathol (2014) 9:147–56. doi: 10.1146/annurev-pathol-012513-104713

34. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, et al. The CD40 Antigen and Its Ligand. Annu Rev Immunol (1994) 12:881–922. doi: 10.1146/annurev.immunol.12.040194.004313

35. Jacobson EM, Huber AK, Akeno N, Sivak M, Li CW, Concepcion E, et al. A CD40 Kozak Sequence Polymorphism and Susceptibility to Antibody-Mediated Autoimmune Conditions: The Role of CD40 Tissue-Specific Expression. Genes Immun (2007) 8(3):205–14. doi: 10.1038/sj.gen.6003457

36. Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, et al. Genetically Driven Target Tissue Overexpression of CD40: A Novel Mechanism in Autoimmune Disease. J Immunol (2012) 189(6):3043–53. doi: 10.4049/jimmunol.1200311

37. Lee HJ, Lombardi A, Stefan M, Li CW, Inabnet WB,3, Owen RP, et al. CD40 Signaling in Graves Disease Is Mediated Through Canonical and Noncanonical Thyroidal Nuclear Factor Kappab Activation. Endocrinology (2017) 158(2):410–6. doi: 10.1210/en.2016-1609

38. Kim TY, Park YJ, Hwang JK, Rolland Y, Cho BY, et al. A C/T Polymorphism in the 5’ Untranslated Region of the CD40 Gene Is Associated With Later Onset of Graves’ Disease in Japanese. Endocr J (2005) 52(4):471–7. doi: 10.1507/endocr.j.52.471

39. Hsiao YJ, Hsieh MC, Hsiao CT, Weng HH, Ke DS. Association of CD40 and Thyroglobulin Genes With Later-Onset Graves’ Disease in Taiwanese Patients. Eur J Endocrinol (2008) 159(5):617–21. doi: 10.1530/EJE-08-0410

40. Inoue N, Watanabe M, Yamada H, Takekura K, Hayashi F, Yamakawa N, et al. Associations Between Autoimmune Thyroid Disease Prognosis and Functional Polymorphisms of Susceptibility Genes, CTLA4, Ptpn22, CD40, FCRL3, and ZFAT, Previously Revealed in Genome-wide Association Studies. J Clin Immunol (2012) 32(6):1243–52. doi: 10.1007/s10875-012-9721-0

41. Zhang QY, Liu W, Li L, Du WH, Zuo CL, Ye XF, et al. Genetic Study in a Large Cohort Supported Different Pathogenesis of Graves’ Disease and Hashimoto’s Hypothyroidism. J Clin Endocrinol Metab (2020) 105(7): e2600–8. doi: 10.1210/cjim/dga1170

42. Mukai T, Horiomatsu Y, Fukutani T, Ichimura M, Kaku H, Miyake I, et al. A C/T Polymorphism in the 5’ Untranslated Region of the CD40 Gene Is Associated With Later Onset of Graves’ Disease in Japanese. Thyroid (2006) 16(5):443–6. doi: 10.1089/thy.2006.16.443

43. Kurylowicz A, Kula D, Ploski R, Skorka A, Jurecka-Lubieniecka B, Zebracka J, et al. Association of CD40 Gene Polymorphism (C-1T) With Susceptibility and Phenotype of Graves’ Disease. Thyroid (2005) 15(10):1119–24. doi: 10.1089/thy.2005.15.1119

Conflict of Interest: YT, GK, and LFa declare that they submitted a Patent Application (US Provisional Application No: 63/120,514) entitled: “Method for predicting patient response to CD40-targeted therapies” which is related to the current manuscript. YT declares that he also submitted two additional patent disclosures that are not related to the content of this manuscript. YT was previously (January 2015 to June 2017) the PI on a basic research project jointly funded by the Juvenile Diabetes Research Foundation and Pfizer. The current manuscript is not related to that research project. GK consults for Immunovant, MedImmune, USM, Mercck, Germany, Novartis, Switzerland, and Quidel, USA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Faustino, Kahaly, Frommer, Concepcion, Stefan-Lifshitz and Tomer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.